SCHEMBL2284643

SCHEMBL2284643

COCCNS(=O)(=O)c1cccc(/C=C/C(=O)c2c(O)cc(C)[nH]c2=O)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 4/20 0.43
HDAC4 P56524 4/20 0.43
HDAC1 Q13547 4/20 0.43
HDAC7 Q8WUI4 4/20 0.43
HDAC2 Q92769 4/20 0.43
HDAC10 Q969S8 4/20 0.43
HDAC11 Q96DB2 4/20 0.43
HDAC8 Q9BY41 4/20 0.43
HDAC6 Q9UBN7 4/20 0.43
HDAC9 Q9UKV0 4/20 0.43
HDAC5 Q9UQL6 4/20 0.43
HTT P42858 5/20 0.41
LMNA P02545 5/20 0.41
MAPT P10636 3/20 0.41
SMN1; SMN2 Q16637 5/20 0.41
NPSR1 Q6W5P4 2/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
POLB P06746 2/20 0.40
PKM P14618 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2284645 1.00 HDAC3 (0.43) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL2284337 0.85 GAA (0.43) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL2284339 0.85 GAA (0.43) HDAC3HDAC4HDAC1HDAC7HDAC2
SCHEMBL2280689 0.82 LMNA (0.43) HTTLMNAMAPTSMN1; SMN2NPSR1
SCHEMBL2280683 0.82 LMNA (0.43) HTTLMNAMAPTSMN1; SMN2NPSR1
SCHEMBL2284238 0.80 LMNA (0.41) HDAC3HDAC1HDAC2HDAC6HTT
SCHEMBL2281145 0.78 LMNA (0.54) HTTLMNAMAPTSMN1; SMN2NPSR1
SCHEMBL2281141 0.78 LMNA (0.54) HTTLMNAMAPTSMN1; SMN2NPSR1
SCHEMBL2274871 0.77 LMNA (0.50) HDAC1HDAC6HTTLMNAMAPT
SCHEMBL2274875 0.77 LMNA (0.50) HDAC1HDAC6HTTLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 HDAC3 1688/4885HDAC4 1273/4885HDAC1 1097/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.